New in JMIR: Assessing ##Patient-Reported Outcomes in Routine #Cancer Clinical Care Using Electronic Administration and #Telehealth Technologies: Realist Synthesis of Potential Mechanisms for Improving Health Outcomes https://t.co/yTz0gRpBxN
Paper available!
Dose-Escalated 2-Fraction Spine Stereotactic Body Radiation Therapy: 28 Gy Versus 24 Gy in 2 Daily Fractions https://t.co/4qFA6xv2vj
#ASTRO22#ASTRO2022
New #OpenAccess review | Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer https://t.co/vLrdsT1m2n @imrtlee@MSK_RadOnc@MSKCancerCenter
Drs Jennie Roberts, Angela Allen and Tuan Ha are our convenors for the 2023 ASM. Our co-convenors introduced the theme for next year at the #RANZCR2022 Gala Dinner, which is BEYOND. We look forward to welcoming you to Brisbane from 19-22 October 2023.
#RANZCR2023
5-yr Outcomes Ph III KN042 trial, Pembro v Chemo in 1L PDL1≥1% NSCLC @JCO_ASCO:
- HR OS in PDL1>50% 0.66, 5yr OS 21.9%
- HR OS in PDL1 1-49% 0.88, 95%CI crosses 1, 5yr OS 11.9%
- 33pts re-challenged w pembro, 15.2% ORR
@OncoAlert #LCSM https://t.co/7ZegsFBnZM
Today is Day 1 of Lung Cancer Awareness Month 2022 (#LCAM22). Fact: Did you know that #LungCancer causes more deaths globally than colon, breast, & prostate cancers combined? #LCSM
🚨New in @CAonline: Review of deintensification for HPV‐positive OPC #headandNeckCancer#hncsm. The future may lie in incorporating intra-tx response assessments to harness the powers of personalized medicine & integrate real-time surveillance. #hncsm
👉https://t.co/rXrJojAygu
The effect of cochlear dose on hearing preservation after low dose stereotactic radiosurgery for vestibular schwannomas: a systematic review https://t.co/jErscM66yS
A practical approach will be to aim for a mean cochlear dose ˂ 4-6 Gy without compromising tumour dose.
To Infinity and Beyond. Thank you to @GEHealthcare for sponsoring last night's Gala Dinner at the Adelaide Convention Centre. Thank you to Ms Julia Keraand, MR Leader for Australia/New Zealand, for joining us on stage last night. Thank you to everyone who attended.
#RANZCR2022
This voluntary, RANZCR approved ANZPROG survey uses 5 case studies to assess the current utilisation of advanced palliative RT techniques & technologies in Australia & New Zealand. Responses will be de-identified & reported in aggregate only.
https://t.co/mYf5jAPWf0